Table 1. Baseline tumor characteristics according with type of lymphoma and HIV status.
| HIV-L | nHIV-L | P- value | total | |
|---|---|---|---|---|
| Non Hodgkin Lymphoma, n (%) | 321 (35) | 588 (64) | 909 | |
| Median Age, (IQR) | 46 (39–52) | 63(49–72) | <0.001 | 54 (44–68) |
| Female, | 54 (17) | 308 (52) | <0.001 | 362 (39.8) |
| HIV transmission route | ||||
| IDU | 63 (21) | |||
| MSM | 55 (18) | |||
| Heterosexual | 74 (24) | |||
| Other/unknown | 114 (37) | 588 (100) | ||
| HbsAg+ | 23 (7) | |||
| Unknown | 88 (27) | 588 (100) | ||
| HCVAb+ | 80 (25) | |||
| Unknown | 52 (16) | 588 (100) | ||
| IPI* score (n = 549) | ||||
| Low | 56 (17) | 149 (25) | 0.02 | 205 (23) |
| intermediate | 98 (30) | 183 (31) | 281 (31) | |
| High | 24 (7) | 39 (7) | 63 (7) | |
| Histotype (n = 901) | ||||
| DLBCL** | 202(65) | 559 (95) | <0.001 | 761 (84) |
| SNCCL ***(Burkitt, Burkitt-like) | 84 (27) | 27 (5) | 111 (12) | |
| IBL° | 21 (6) | 2 (0.3) | 23 (3) | |
| PBL§ | 6 (2) | 0 (0) | 6 (1) | |
| First line chemotherapy (n = 868) | 300 (93) | 551 (94) | <0.001 | 851 (94) |
| SNC°° prophylaxis (n = 607) | 145 (45) | 109 (18) | <0.001 | 254 (28) |
| CHOP+, CHOP-like++ regimens (n = 809) | 230 (72) | 419 (71) | 0.001 | 649 (71) |
| Other regimens (n = 909) | 82 (25) | 116 (20) | 0.04 | 198 (22) |
| Use of rituximab (n = 762) | 172 (54) | 387 (66) | 0.001 | 599 (61) |
| Hodgkin’s lymphoma, n (%) | 145 (32) | 278 (32) | 423 | |
| Median Age, (IQR) | 46 (39–52) | 63(49–72) | <0.001 | 54 (44–68) |
| Female, | 16 (11) | 140 (50) | <0.001 | 156 (37) |
| HIV transmission route | ||||
| IDU | 23 (16.5) | |||
| MSM | 33 (24) | |||
| Heterosexual | 42 (30) | |||
| Other/unknown | 41 (29) | 278 (100) | ||
| HbsAg+ | 14 (10) | |||
| Unknown | 36 (25) | 278 (100) | ||
| HCVAb+ | 35 (24) | |||
| Unknown | 14 (10) | 278 (100) | ||
| Histotype (n = 422) | ||||
| Nodular sclerosing | 32(22) | 195 (70) | <0.001 | 227 (54) |
| Mixed cellular | 51 (35) | 15 (5) | 66 (16) | |
| Lymphocyte-depleted | 4 (3) | 5 (2) | 9 (2) | |
| Lymphocyte-rich | 7 (5) | 15 (5) | 22 (5) | |
| unspecified | 50 (34) | 48 (17) | 98 (23) | |
| Ann Arbor stage (n = 405) | ||||
| 1 | 66 (46) | 86 (31) | 0.02 | 152 (36) |
| 2 | 32 (22) | 127 (46) | 159 (38) | |
| 3 | 36 (25) | 58 (21) | 94 (22) | |
| 4 | 50 (35) | 69 (25) | 119 (28) | |
| First line chemotherapy (n = 419) | 134 (93) | 277 (99) | 0.004 | 411 (97) |
| ABVD# (n = 392) | 111 (96) | 160 (58) | <0.001 | 271 (69) |
| VEBEP## (n = 359) | 29 (20) | 0 | <0.001 | 29 (7) |
| BEACOPP### (347) | 16 (11) | 56 (20) | 0.59 | 72 (17) |
In parentheses after each variable, numbers of patients with available datum are reported, when applicable.
*International prognostic Index;
** Diffuse large B cell lymphoma;
***small non cleaved cell lymphoma;
° immunoblastic lymphoma;
§ plasmablastic lymphoma;
°°central nervous system;
+ cyclophosphamide, Adriamycin, vincristine, prednisone;
++ regimens containing at least cyclophosphamide,adriamycin;
# doxorubicin, bleomycin+vinblastine, dacarbazine;
## vincristine, epidoxorubicin, bleomycin, cyclophosphamide, etoposide, prednisone;
### bleomycin, etoposide, Adriamycin, cyclophosphamide, vincristine, procarbazne, prednisone.